Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
Terminated
Henry Ford Health System
Phase 4
2011-10-01
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of
vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed
and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical
concern. This may be due to various reasons, including new dosing recommendations as well as
an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity.
This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin
use.
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
Completed
AstraZeneca
Phase 2/Phase 3
2011-12-01
This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil
in children with skin infections receiving antibiotic therapy in the hospital.
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
Completed
Forest Laboratories
Phase 2/Phase 3
2011-12-01
This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil
in children with skin infections receiving antibiotic therapy in the hospital.
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
Completed
Forest Laboratories
Phase 4
2012-02-01
This study will further analyze the use of ceftaroline for CABP and compare its potential to
eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of
ceftaroline compared to levofloxacin may be further highlighted from this investigation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
